Volasertib (BI 6727) 是一种具有口服活性的、高效的、ATP 竞争性的 Polo 样激酶 1 (
PLK1) 抑制剂，
IC50为 0.87 nM。Volasertib 抑制 PLK2 和 PLK3，
IC50分别为 5 和 56 nM。Volasertib 诱导有丝分裂停滞和细胞凋亡。Volasertib 是一种二氢蝶呤酮衍生物，在多种癌症模型中显示出显着的抗肿瘤活性。
| 生物活性 |
Volasertib (BI 6727) is an orally active, highly potent and ATP-competitivePolo-like kinase1 (PLK1)inhibitor with anIC50of 0.87 nM. Volasertib inhibitsPLK2andPLK3withIC50s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest andapoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiplecancermodels[1][2].
|
| IC50& Target[3] |
PLK1 0.87 nM (IC50) |
PLK2 5 nM (IC50) |
PLK3 56 nM (IC50) |
|
体外研究
(In Vitro) |
Volasertib (BI 6727; 0.01-10000 nM; 72 hours) has EC50values of 11 to 37 nmol/L in multiple cell lines[1].
Volasertib (10-1000 nM; 24 hours) results accumulation of cells with 4N DNA content, indicative of a cell cycle block in G2-M phase[1].
Volasertib (100 nM; 24-72 hours) induces cell apoptosis at 48 hours[1].
Cell Proliferation Assay[1]
| Cell Line: |
Multiple cell lines |
| Concentration: |
0.01-10000 nM |
| Incubation Time: |
72 hours |
| Result: |
Inhibited proliferation of multiple cell lines derived from various cancer tissues, including carcinomas of the colon (HCT 116, EC50=23 nmol/L) and lung (NCI-H460, EC50=21 nmol/L), melanoma (BRO, EC50=11 nmol/L), and hematopoietic cancers (GRANTA-519, EC50=15 nmol/L; HL-60, EC50=32 nmol/L; THP-1, E50=36 nmol/L and Raji, EC50=37 nmol/L) with EC50values of 11 to 37 nmol/L. |
Apoptosis Analysis[1]
| Cell Line: |
NCI-H460 cells |
| Concentration: |
100 nM |
| Incubation Time: |
24, 48, 72 hours |
| Result: |
G2-M arrest at 24 hours was followed by induction of apoptosis at 48 hours. |
Cell Cycle Analysis[1]
| Cell Line: |
NCI-H460 cells |
| Concentration: |
10, 30, 100, 300, 1000 nM |
| Incubation Time: |
24 hours |
| Result: |
Resulted in accumulation of cells with 4N DNA content, indicative of a cell cycle block in G2-M phase. |
|
体内研究
(In Vivo) |
Volasertib (BI 6727; A total weekly dose of 50 mg/kg; Oral; once a week, twice a week, or daily; for 40 days) shows comparable efficacy in human colon carcinoma xenograft models[1].
Volasertib (15, 20, or 25 mg/kg/day; i.v.; 2 consecutive days per week; for 40 days) leads to significant tumor growth delay and even tumor regression in human colon carcinoma xenograft models[1].
Volasertib (70 mg/kg given once weekly or 10 mg/kg daily; oral) significantly delays tumor growth in a non-small cell lung carcinoma xenograft model derived from NCI-H460 cells[1].
Volasertib (a single dose of 40 mg/kg; iv) causes a significant (13-fold) increase in mitotic cells in HCT 116 tumor-bearing nude mice[1].
Volasertib has high volume of distribution and a long terminal half-life in mice (Vss=7.6 L/kg, t1/2=46 h) and rats (Vss=22 L/kg, t1/2=54 h)[1].
| Animal Model: |
Female BomTac:NMRI-Foxn1numice (Taconic) were grafted s.c. with HCT 116 human colon carcinoma cells (ATCC CCL-247)[1] |
| Dosage: |
A total weekly dose of 50 mg/kg |
| Administration: |
Oral; once a week, twice a week, or daily; for 40 days |
| Result: |
Showed comparable efficacy and were well tolerated. |
| Animal Model: |
Female BomTac:NMRI-Foxn1numice and male Wistar rats of the strain Crl:WI[1] |
| Dosage: |
35 mg/kg (mice) or 10 mg/kg (rat) (Pharmacokinetic Analysis) |
| Administration: |
IV 5-minute infusion; a single dose 5-minute infusion |
| Result: |
Had high volume of distribution and a long terminal half-life in mice (Vss=7.6 L/kg, t1/2=46 h) and rats (Vss=22 L/kg, t1/2=54 h). |
|
| Clinical Trial |
|
| 分子量 |
|
| 性状 |
|
| Formula |
|
| CAS 号 |
|
| 中文名称 |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
4°C, protect from light
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
|
| 溶解性数据 |
In Vitro:
DMSO : 50 mg/mL(80.80 mM;Need ultrasonic)
配制储备液
| 1 mM |
1.6160 mL |
8.0800 mL |
16.1600 mL |
| 5 mM |
0.3232 mL |
1.6160 mL |
3.2320 mL |
| 10 mM |
0.1616 mL |
0.8080 mL |
1.6160 mL |
*
请根据半岛bd体育手机客户端 在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的半岛bd体育手机客户端 失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。
In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
-
1.
请依序添加每种溶剂： 10% DMSO40%PEG3005%Tween-8045% saline
Solubility: ≥ 2.08 mg/mL (3.36 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.36 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
-
2.
请依序添加每种溶剂： 10% DMSO90% (20%SBE-β-CDin saline)
Solubility: 2.08 mg/mL (3.36 mM); Suspended solution; Need ultrasonic
此方案可获得 2.08 mg/mL (3.36 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
-
3.
请依序添加每种溶剂： 10% DMSO90%corn oil
Solubility: ≥ 2.08 mg/mL (3.36 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.36 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
*
以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com
